What is the recommended lorlatinib dosing schedule, including dose reductions for toxicity, hepatic impairment, CYP3A interactions, and age limits?

Lorlatinib Dosing

The recommended starting dose of lorlatinib is 100 mg orally once daily, taken with or without food, and continued until disease progression or unacceptable toxicity. 1

Standard Dosing

• Starting dose: 100 mg once daily 1
• Administration: Can be taken with or without food (no clinically significant food effect) 1
• Duration: Continue until disease progression or unacceptable toxicity 2

Dose Reductions for Toxicity

Lorlatinib requires dose modifications for adverse events, which are common but manageable without compromising efficacy 2, 3:

Dose reduction schedule: 1

• First reduction: 75 mg once daily
• Second reduction: 50 mg once daily
• Discontinue if unable to tolerate 50 mg once daily

Common toxicities requiring dose adjustment: 4

• Hyperlipidemia (grade 3-4): Occurs in 31% of patients; manage with lipid-lowering agents (81% of patients require them) and consider dose reduction if uncontrolled 5, 4
• CNS effects (grade 3-4): Occur in 13% of patients; includes cognitive effects, mood changes, speech difficulties; may require dose interruption or reduction 2, 4
• Edema (grade 3-4): Occurs in 11% of patients; manage with diuretics and dose modification if severe 4
• Peripheral neuropathy: Reported in 44% of patients; dose modification indicated for severe cases 4

Dose modification strategy: Hold lorlatinib until toxicity resolves to grade ≤1, then resume at reduced dose 1, 4

Hepatic Impairment

• Mild hepatic impairment (Child-Pugh A): No dose adjustment required 1
• Moderate to severe hepatic impairment (Child-Pugh B or C): Effect unknown; use with caution as pharmacokinetic data are unavailable 1

Renal Impairment

• Mild to moderate renal impairment (CrCl 30-89 mL/min): No dose adjustment required 1
• Severe renal impairment (CrCl 15-29 mL/min): Lorlatinib AUC increased by 42%; reduce starting dose to 75 mg once daily 1
• End-stage renal disease requiring hemodialysis: Not studied; use with extreme caution 1

CYP3A Drug Interactions

Lorlatinib is primarily metabolized by CYP3A4, making drug interactions clinically significant 1:

Strong CYP3A Inhibitors

• Avoid concomitant use with strong CYP3A inhibitors (e.g., itraconazole, ketoconazole, ritonavir, cobicistat) 1, 6
• If unavoidable: Reduce lorlatinib starting dose from 100 mg to 75 mg once daily 1, 6
• Itraconazole increases lorlatinib AUC by 42% and Cmax by 24% 1, 6

Moderate CYP3A Inhibitors

• Fluconazole predicted to increase lorlatinib AUC by 59%; reduce dose to 75 mg once daily 1
• Verapamil and erythromycin: No clinically significant effect predicted 1

Strong CYP3A Inducers

• Contraindicated: Avoid rifampin, carbamazepine, phenytoin, St. John's wort 1, 7
• Rifampin reduces lorlatinib AUC by 85% and Cmax by 76%, rendering treatment ineffective 1, 7
• Critical warning: Rifampin coadministration caused severe transaminase elevations (grade 2-4 in all subjects within 1-3 days) 1, 7

Moderate CYP3A Inducers

• Modafinil decreases lorlatinib AUC by 23%; avoid if possible or monitor closely 1

Lorlatinib as an Inducer

• Lorlatinib induces CYP3A4 (autoinduction occurs at steady-state) 1
• Reduces exposure of CYP3A substrates (e.g., midazolam by 64%), P-gp substrates (e.g., fexofenadine by 67%), and hormonal contraceptives 1
• Use alternative non-hormonal contraception 1

Age Considerations

• No age-specific dose adjustments: Lorlatinib pharmacokinetics are not significantly affected by age (studied in patients 19-85 years) 1
• Pediatric use: Safety and efficacy not established in patients <18 years 8

Therapeutic Drug Monitoring

Emerging evidence suggests serum lorlatinib concentrations correlate with adverse events 5:

• Grade ≥3 AEs associated with higher concentrations: Median 462 ng/mL vs. 177 ng/mL in patients without severe AEs (p<0.01) 5
• Dose modifications successfully reduced serum concentrations and managed toxicity without compromising progression-free survival 5
• Consider therapeutic drug monitoring in patients with severe or persistent toxicities 5

Clinical Efficacy Context

Lorlatinib is recommended as a first-line option for ALK-rearranged NSCLC alongside alectinib and brigatinib, though the recommendation strength is weak due to immature overall survival data and increased toxicity compared to alectinib 2. The CROWN trial demonstrated superior progression-free survival (HR 0.28,95% CI 0.19-0.41) compared to crizotinib, with effective CNS penetration (brain-to-plasma ratio 0.82) 2, 9.

Key pitfall: The distinct adverse event profile (hyperlipidemia, CNS effects, weight gain) requires proactive monitoring and management with lipid-lowering agents, dose modifications, and patient education to maintain treatment adherence and quality of life 4, 3.